Search

Your search keyword '"Rushing, Elisabeth J"' showing total 757 results
Start Over Author "Rushing, Elisabeth J"
757 results on '"Rushing, Elisabeth J"'

1. High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity

Author

Lee, Sohyon, Weiss, Tobias, Bühler, Marcel, Mena, Julien, Lottenbach, Zuzanna, Wegmann, Rebekka, Sun, Miaomiao, Bihl, Michel, Augustynek, Bartłomiej, Baumann, Sven P., Goetze, Sandra, van Drogen, Audrey, Pedrioli, Patrick G. A., Penton, David, Festl, Yasmin, Buck, Alicia, Kirschenbaum, Daniel, Zeitlberger, Anna M., Neidert, Marian C., Vasella, Flavio, Rushing, Elisabeth J., Wollscheid, Bernd, Hediger, Matthias A., Weller, Michael, and Snijder, Berend

Published
2024
Full Text
View/download PDF

6. Expanding the spectrum of low‐grade sinonasal adenocarcinoma with biphasic seromucinous differentiation and activating HRAS/AKT1 mutations.

Author

Hadnagy, Viktoria S, Körner, Meike, Rössle, Matthias, Dubach, Patrick, Pabst, Gunther, Kotulova, Alexandra, Weder, Stefan, Seifert, Robert, Rushing, Elisabeth J, Holzmann, David, Hüllner, Martin, Freiberger, Sandra N, and Rupp, Niels J

Subjects
PARANASAL sinuses, NASAL cavity, IMMUNOSTAINING, ADENOCARCINOMA, TUMORS
Abstract

Aims: Low‐grade non‐intestinal‐type sinonasal adenocarcinoma (LGSNAC) is a rare heterogeneous and poorly characterised group of tumours, distinct from intestinal‐ and salivary‐type neoplasms. Therefore, further characterisation is needed for clearer biological understanding and classification. Methods and results: Clinical, histological and molecular characterisation of four cases of biphasic, low‐grade adenocarcinomas of the sinonasal tract was performed. All patients were male, aged between 48 and 78 years, who presented with polypoid masses in the nasal cavity. Microscopically, virtually all tumours were dominated by tubulo‐glandular biphasic patterns, microcystic, focal (micro)papillary, oncocytic or basaloid features. Immunohistochemical staining confirmed biphasic differentiation with an outer layer of myoepithelial cells. Molecular profiling revealed HRAS (p.G13R, p.Q61R) mutations, and concomitant AKT1 (p.E17K, p.Q79R) mutations in two cases. Two cases showed potential in‐situ/precursor lesions adjacent to the tumour. Follow‐up periods ranged from 1 to 30 months, with one case relapsing locally after 12 and > 20 years. Conclusion: This study further corroborates a distinct biphasic low‐grade neoplasm of the sinonasal tract with seromucinous differentiation. Although morphological and molecular features overlap with salivary gland epithelial–myoepithelial carcinoma, several arguments favour categorising these tumours within the spectrum of LGSNAC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Alterations in homologous recombination repair genes in prostate cancer brain metastases

Author

Rodriguez-Calero, Antonio, Gallon, John, Akhoundova, Dilara, Maletti, Sina, Ferguson, Alison, Cyrta, Joanna, Amstutz, Ursula, Garofoli, Andrea, Paradiso, Viola, Tomlins, Scott A., Hewer, Ekkehard, Genitsch, Vera, Fleischmann, Achim, Vassella, Erik, Rushing, Elisabeth J., Grobholz, Rainer, Fischer, Ingeborg, Jochum, Wolfram, Cathomas, Gieri, Osunkoya, Adeboye O., Bubendorf, Lukas, Moch, Holger, Thalmann, George, Ng, Charlotte K. Y., Gillessen, Silke, Piscuoglio, Salvatore, and Rubin, Mark A.

Published
2022
Full Text
View/download PDF

8. Telomerase reverse transcriptase promoter mutation– and O6-methylguanine DNA methyltransferase promoter methylation–mediated sensitivity to temozolomide in isocitrate dehydrogenase–wild-type glioblastoma: is there a link?

Author

Gramatzki, Dorothee, Felsberg, Jörg, Hentschel, Bettina, Wolter, Marietta, Schackert, Gabriele, Westphal, Manfred, Regli, Luca, Thon, Niklas, Tatagiba, Marcos, Wick, Wolfgang, Schlegel, Uwe, Krex, Dietmar, Matschke, Jakob, Roth, Patrick, Suresh, Marian P., Kamp, Marcel A., Rushing, Elisabeth J., Pietsch, Torsten, von Deimling, Andreas, Sabel, Michael, Loeffler, Markus, Weller, Michael, and Reifenberger, Guido

Published
2021
Full Text
View/download PDF

16. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

Author

Johnson, Douglas B., McDonnell, Wyatt J., Gonzalez-Ericsson, Paula I., Al-Rohil, Rami N., Mobley, Bret C., Salem, Joe-Elie, Wang, Daniel Y., Sanchez, Violeta, Wang, Yu, Chastain, Cody A., Barker, Kristi, Liang, Yan, Warren, Sarah, Beechem, Joseph M., Menzies, Alexander M., Tio, Martin, Long, Georgina V., Cohen, Justine V., Guidon, Amanda C., O’Hare, Méabh, Chandra, Sunandana, Chowdhary, Akansha, Lebrun-Vignes, Bénédicte, Goldinger, Simone M., Rushing, Elisabeth J., Buchbinder, Elizabeth I., Mallal, Simon A., Shi, Chanjuan, Xu, Yaomin, Moslehi, Javid J., Sanders, Melinda E., Sosman, Jeffrey A., and Balko, Justin M.

Published
2019
Full Text
View/download PDF

17. Primary spinal cord tumors of childhood: effects of clinical presentation, radiographic features, and pathology on survival

Author

Crawford, John R., Zaninovic, Alejandra, Santi, Mariarita, Rushing, Elisabeth J., Olsen, Cara H., Keating, Robert F., Vezina, Gilbert, Kadom, Nadja, and Packer, Roger J.

Subjects
Medicine & Public Health, Neurology, Oncology, Pediatric spinal cord tumor, Intraspinal tumor, Childhood spinal tumor
Abstract

To determine the relationship between clinical presentation, radiographic features, pathology, and treatment on overall survival of newly diagnosed pediatric primary spinal cord tumors (PSCT). Retrospective analysis of all previously healthy children with newly diagnosed PSCT at a single institution from 1995 to present was performed. Twenty-five pediatric patients (15 boys, average 7.9 years) were diagnosed with PSCT. Presenting symptoms ranged from 0.25 to 60 months (average 7.8 months). Symptom duration was significantly shorter for high grade tumors (average 1.65 months) than low grade tumors (average 11.2 months) (P = 0.05). MRI revealed tumor (8 cervical, 17 thoracic, 7 lumbar, 7 sacral) volumes of 98–94,080 mm3 (average 19,474 mm3). Homogeneous gadolinium enhancement on MRI correlated with lower grade pathology (P = 0.003). There was no correlation between tumor grade and volume (P = 0.63) or edema (P = 0.36) by MRI analysis. Median survival was 53 months and was dependent on tumor grade (P = 0.05) and gross total resection (P = 0.01) but not on gender (P = 0.49), age of presentation (P = 0.82), duration of presenting symptoms (P = 0.33), or adjuvant therapies (P = 0.17). Stratified Kaplan–Meier analysis confirmed the association between degree of resection and survival after controlling for tumor grade (P = 0.01). MRI homogeneous gadolinium enhancement patterns may be helpful in distinguishing low grade from high grade spinal cord malignancies. While tumor grade and gross total resection rather than duration of symptoms correlated with survival in our series, greater than one-third of patients had reported symptoms greater than 6 months duration prior to diagnosis.

Published
2009

18. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis

Author

Sahm, Felix, Schrimpf, Daniel, Stichel, Damian, Jones, David T W, Hielscher, Thomas, Schefzyk, Sebastian, Okonechnikov, Konstantin, Koelsche, Christian, Reuss, David E, Capper, David, Sturm, Dominik, Wirsching, Hans-Georg, Berghoff, Anna Sophie, Baumgarten, Peter, Kratz, Annekathrin, Huang, Kristin, Wefers, Annika K, Hovestadt, Volker, Sill, Martin, Ellis, Hayley P, Kurian, Kathreena M, Okuducu, Ali Fuat, Jungk, Christine, Drueschler, Katharina, Schick, Matthias, Bewerunge-Hudler, Melanie, Mawrin, Christian, Seiz-Rosenhagen, Marcel, Ketter, Ralf, Simon, Matthias, Westphal, Manfred, Lamszus, Katrin, Becker, Albert, Koch, Arend, Schittenhelm, Jens, Rushing, Elisabeth J, Collins, V Peter, Brehmer, Stefanie, Chavez, Lukas, Platten, Michael, Hänggi, Daniel, Unterberg, Andreas, Paulus, Werner, Wick, Wolfgang, Pfister, Stefan M, Mittelbronn, Michel, Preusser, Matthias, Herold-Mende, Christel, Weller, Michael, and von Deimling, Andreas

Published
2017
Full Text
View/download PDF

20. Data from DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations

Author

Gallon, John, primary, Rodriguez-Calero, Antonio, primary, Benjak, Andrej, primary, Akhoundova, Dilara, primary, Maletti, Sina, primary, Amstutz, Ursula, primary, Hewer, Ekkehard, primary, Genitsch, Vera, primary, Fleischmann, Achim, primary, Rushing, Elisabeth J., primary, Grobholz, Rainer, primary, Fischer, Ingeborg, primary, Jochum, Wolfram, primary, Cathomas, Gieri, primary, Osunkoya, Adeboye O., primary, Bubendorf, Lukas, primary, Moch, Holger, primary, Thalmann, George, primary, Feng, Felix Y., primary, Gillessen, Silke, primary, Ng, Charlotte K.Y., primary, Rubin, Mark A., primary, and Piscuoglio, Salvatore, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Data from DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations

Author

Gallon, John, primary, Rodriguez-Calero, Antonio, primary, Benjak, Andrej, primary, Akhoundova, Dilara, primary, Maletti, Sina, primary, Amstutz, Ursula, primary, Hewer, Ekkehard, primary, Genitsch, Vera, primary, Fleischmann, Achim, primary, Rushing, Elisabeth J., primary, Grobholz, Rainer, primary, Fischer, Ingeborg, primary, Jochum, Wolfram, primary, Cathomas, Gieri, primary, Osunkoya, Adeboye O., primary, Bubendorf, Lukas, primary, Moch, Holger, primary, Thalmann, George, primary, Feng, Felix Y., primary, Gillessen, Silke, primary, Ng, Charlotte K.Y., primary, Rubin, Mark A., primary, and Piscuoglio, Salvatore, primary

Published
2023
Full Text
View/download PDF

22. DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations

Author

Gallon, John; https://orcid.org/0000-0002-5328-6298, Rodriguez-Calero, Antonio; https://orcid.org/0000-0002-2744-2381, Benjak, Andrej; https://orcid.org/0000-0003-4522-6575, Akhoundova, Dilara; https://orcid.org/0000-0003-1639-3059, Maletti, Sina; https://orcid.org/0000-0002-8678-0321, Amstutz, Ursula; https://orcid.org/0000-0002-0880-456X, Hewer, Ekkehard; https://orcid.org/0000-0002-9128-0364, Genitsch, Vera; https://orcid.org/0000-0003-1476-9980, Fleischmann, Achim; https://orcid.org/0000-0002-2894-4201, Rushing, Elisabeth J; https://orcid.org/0000-0001-7616-6320, Grobholz, Rainer; https://orcid.org/0000-0002-1901-7967, Fischer, Ingeborg; https://orcid.org/0000-0002-7659-3899, Jochum, Wolfram; https://orcid.org/0000-0001-6170-2020, Cathomas, Gieri; https://orcid.org/0000-0003-1276-4940, Osunkoya, Adeboye O; https://orcid.org/0000-0001-5712-8134, Bubendorf, Lukas; https://orcid.org/0000-0001-5970-1803, Moch, Holger; https://orcid.org/0000-0002-7986-2839, Thalmann, George; https://orcid.org/0000-0002-1908-3286, Feng, Felix Y; https://orcid.org/0000-0002-0963-7687, Gillessen, Silke; https://orcid.org/0000-0001-5746-6555, Ng, Charlotte K Y; https://orcid.org/0000-0002-6100-0026, Rubin, Mark A; https://orcid.org/0000-0002-8321-9950, Piscuoglio, Salvatore; https://orcid.org/0000-0003-2686-2939, Gallon, John; https://orcid.org/0000-0002-5328-6298, Rodriguez-Calero, Antonio; https://orcid.org/0000-0002-2744-2381, Benjak, Andrej; https://orcid.org/0000-0003-4522-6575, Akhoundova, Dilara; https://orcid.org/0000-0003-1639-3059, Maletti, Sina; https://orcid.org/0000-0002-8678-0321, Amstutz, Ursula; https://orcid.org/0000-0002-0880-456X, Hewer, Ekkehard; https://orcid.org/0000-0002-9128-0364, Genitsch, Vera; https://orcid.org/0000-0003-1476-9980, Fleischmann, Achim; https://orcid.org/0000-0002-2894-4201, Rushing, Elisabeth J; https://orcid.org/0000-0001-7616-6320, Grobholz, Rainer; https://orcid.org/0000-0002-1901-7967, Fischer, Ingeborg; https://orcid.org/0000-0002-7659-3899, Jochum, Wolfram; https://orcid.org/0000-0001-6170-2020, Cathomas, Gieri; https://orcid.org/0000-0003-1276-4940, Osunkoya, Adeboye O; https://orcid.org/0000-0001-5712-8134, Bubendorf, Lukas; https://orcid.org/0000-0001-5970-1803, Moch, Holger; https://orcid.org/0000-0002-7986-2839, Thalmann, George; https://orcid.org/0000-0002-1908-3286, Feng, Felix Y; https://orcid.org/0000-0002-0963-7687, Gillessen, Silke; https://orcid.org/0000-0001-5746-6555, Ng, Charlotte K Y; https://orcid.org/0000-0002-6100-0026, Rubin, Mark A; https://orcid.org/0000-0002-8321-9950, and Piscuoglio, Salvatore; https://orcid.org/0000-0003-2686-2939

Abstract

UNLABELLED Metastases from primary prostate cancers to rare locations, such as the brain, are becoming more common due to longer life expectancy resulting from improved treatments. Epigenetic dysregulation is a feature of primary prostate cancer, and distinct DNA methylation profiles have been shown to be associated with the mutually exclusive SPOP-mutant or TMPRSS2-ERG fusion genetic backgrounds. Using a cohort of prostate cancer brain metastases (PCBM) from 42 patients, with matched primary tumors for 17 patients, we carried out a DNA methylation analysis to examine the epigenetic distinction between primary prostate cancer and PCBM, the association between epigenetic alterations and mutational background, and particular epigenetic alterations that may be associated with PCBM. Multiregion sampling of PCBM revealed epigenetic stability within metastases. Aberrant methylation in PCBM was associated with mutational background and PRC2 complex activity, an effect that is particularly pronounced in SPOP-mutant PCBM. While PCBM displayed a CpG island hypermethylator phenotype, hypomethylation at the promoters of genes involved in neuroactive ligand-receptor interaction and cell adhesion molecules such as GABRB3, CLDN8, and CLDN4 was also observed, suggesting that cells from primary tumors may require specific reprogramming to form brain metastasis. This study revealed the DNA methylation landscapes of PCBM and the potential mechanisms and effects of PCBM-associated aberrant DNA methylation. SIGNIFICANCE DNA methylation analysis reveals the molecular characteristics of PCBM and may serve as a starting point for efforts to identify and target susceptibilities of these rare metastases.

Published
2023

23. Gustatory Function of Patients With and Without Cholesteatoma Undergoing Middle Ear Surgery

Author

Neumann, Aline Sophie; https://orcid.org/0000-0002-2140-9505, Soyka, Michael B, Rushing, Elisabeth J, Röösli, Christof, Neumann, Aline Sophie; https://orcid.org/0000-0002-2140-9505, Soyka, Michael B, Rushing, Elisabeth J, and Röösli, Christof

Abstract

Objective: To compare measured and perceived taste function before and after surgery of patients with chronic otitis media with cholesteatoma (OMCC) to patients without cholesteatoma (patients with chronic suppurative otitis media [CSOM] and patients with lateral skull base lesions [LSB]). Methods: This prospective cohort study included 29 patients undergoing surgery for unilateral OMCC. The chorda tympani nerve (CTN) was resected in 8 of these patients. Fourteen patients undergoing surgery for unilateral CSOM and 5 patients undergoing surgery for unilateral LSB (with CTN resection) served as the comparison group. Taste function was measured using taste strips on both sides of the tongue before surgery, 2 weeks postoperatively and 3 months postoperatively. The affected side of the tongue was compared to the unaffected side. A questionnaire on taste perception was completed at each visit. Results: Preoperatively, cholesteatoma patients showed higher taste strip scores than non-cholesteatoma patients, indicating a larger difference between the healthy and affected sides of the tongue. Despite this difference in measured taste function few cholesteatoma patients reported taste alteration before surgery (3/29 [10.3%]). Postoperatively, patients with CTN resection (OMCC patients with CTN resection and LSB patients) showed a decreased measured taste function. Subjectively, only approximately 20% of these patients reported taste alteration 3 months postoperatively. Conclusions: Before surgery, cholesteatoma patients displayed an impaired measured taste function compared to patients without cholesteatoma (CSOM, LSB). Subjectively this was often unnoticed. After surgery, despite removal of the CTN and consequent reduction of measured taste function, few patients reported taste alteration and subjective taste perception was seen to be improving. In regards to middle ear surgery, perceived taste function does not seem to reflect measured gustatory function.

Published
2023

25. DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations

Author

Gallon, John, primary, Rodriguez-Calero, Antonio, additional, Benjak, Andrej, additional, Akhoundova, Dilara, additional, Maletti, Sina, additional, Amstutz, Ursula, additional, Hewer, Ekkehard, additional, Genitsch, Vera, additional, Fleischmann, Achim, additional, Rushing, Elisabeth J., additional, Grobholz, Rainer, additional, Fischer, Ingeborg, additional, Jochum, Wolfram, additional, Cathomas, Gieri, additional, Osunkoya, Adeboye O., additional, Bubendorf, Lukas, additional, Moch, Holger, additional, Thalmann, George, additional, Feng, Felix Y., additional, Gillessen, Silke, additional, Ng, Charlotte K.Y., additional, Rubin, Mark A., additional, and Piscuoglio, Salvatore, additional

Published
2023
Full Text
View/download PDF

27. Exercise effects in Huntington disease

Author

Frese, Sebastian, Petersen, Jens A., Ligon-Auer, Maria, Mueller, Sandro Manuel, Mihaylova, Violeta, Gehrig, Saskia M., Kana, Veronika, Rushing, Elisabeth J., Unterburger, Evelyn, Kägi, Georg, Burgunder, Jean-Marc, Toigo, Marco, and Jung, Hans H.

Published
2017
Full Text
View/download PDF

30. Gustatory Function of Patients With and Without Cholesteatoma Undergoing Middle Ear Surgery

Author

Neumann, Aline Sophie, Soyka, Michael B, Rushing, Elisabeth J, Röösli, Christof, and University of Zurich

Subjects
Otorhinolaryngology, 610 Medicine & health, 10045 Clinic for Otorhinolaryngology, General Medicine
Abstract

Objective: To compare measured and perceived taste function before and after surgery of patients with chronic otitis media with cholesteatoma (OMCC) to patients without cholesteatoma (patients with chronic suppurative otitis media [CSOM] and patients with lateral skull base lesions [LSB]). Methods: This prospective cohort study included 29 patients undergoing surgery for unilateral OMCC. The chorda tympani nerve (CTN) was resected in 8 of these patients. Fourteen patients undergoing surgery for unilateral CSOM and 5 patients undergoing surgery for unilateral LSB (with CTN resection) served as the comparison group. Taste function was measured using taste strips on both sides of the tongue before surgery, 2 weeks postoperatively and 3 months postoperatively. The affected side of the tongue was compared to the unaffected side. A questionnaire on taste perception was completed at each visit. Results: Preoperatively, cholesteatoma patients showed higher taste strip scores than non-cholesteatoma patients, indicating a larger difference between the healthy and affected sides of the tongue. Despite this difference in measured taste function few cholesteatoma patients reported taste alteration before surgery (3/29 [10.3%]). Postoperatively, patients with CTN resection (OMCC patients with CTN resection and LSB patients) showed a decreased measured taste function. Subjectively, only approximately 20% of these patients reported taste alteration 3 months postoperatively. Conclusions: Before surgery, cholesteatoma patients displayed an impaired measured taste function compared to patients without cholesteatoma (CSOM, LSB). Subjectively this was often unnoticed. After surgery, despite removal of the CTN and consequent reduction of measured taste function, few patients reported taste alteration and subjective taste perception was seen to be improving. In regards to middle ear surgery, perceived taste function does not seem to reflect measured gustatory function.

Published
2022

31. Targeting tumour-intrinsic neural vulnerabilities of glioblastoma

Author

Lee, Sohyon, primary, Weiss, Tobias, additional, Bühler, Marcel, additional, Mena, Julien, additional, Lottenbach, Zuzanna, additional, Wegmann, Rebekka, additional, Sun, Miaomiao, additional, Bihl, Michel, additional, Augustynek, Bartłomiej, additional, Baumann, Sven, additional, Goetze, Sandra, additional, van Drogen, Audrey, additional, Pedrioli, Patrick, additional, Kirschenbaum, Daniel, additional, Vasella, Flavio, additional, Rushing, Elisabeth J., additional, Wollscheid, Bernd, additional, Hediger, Matthias A., additional, Michael, Weller, additional, and Snijder, Berend, additional

Published
2022
Full Text
View/download PDF

33. Diagnostic red flags: steroid‐treated malignant CNS lymphoma mimicking autoimmune inflammatory demyelination

Author

Barrantes‐Freer, Alonso, Engel, Aylin Sophie, Rodríguez‐Villagra, Odir Antonio, Winkler, Anne, Bergmann, Markus, Mawrin, Christian, Kuempfel, Tania, Pellkofer, Hannah, Metz, Imke, Bleckmann, Annalen, Hernández‐Durán, Silvia, Schippling, Sven, Rushing, Elisabeth J., Frank, Stephan, Glatzel, Markus, Matschke, Jakob, Hartmann, Christian, Reifenberger, Guido, Müller, Wolf, Schildhaus, Hans‐Ulrich, Brück, Wolfgang, and Stadelmann, Christine

Published
2018
Full Text
View/download PDF

34. Gustatory Function of Patients With and Without Cholesteatoma Undergoing Middle Ear Surgery.

Author

Neumann, Aline Sophie, Soyka, Michael B., Rushing, Elisabeth J., and Röösli, Christof

Subjects
FACIAL nerve surgery, MIDDLE ear surgery, CHRONIC diseases, CHOLESTEATOMA, TREATMENT effectiveness, COMPARATIVE studies, DESCRIPTIVE statistics, QUESTIONNAIRES, TASTE, OTITIS media, SKULL tumors, LONGITUDINAL method, EVALUATION
Abstract

Objective: To compare measured and perceived taste function before and after surgery of patients with chronic otitis media with cholesteatoma (OMCC) to patients without cholesteatoma (patients with chronic suppurative otitis media [CSOM] and patients with lateral skull base lesions [LSB]). Methods: This prospective cohort study included 29 patients undergoing surgery for unilateral OMCC. The chorda tympani nerve (CTN) was resected in 8 of these patients. Fourteen patients undergoing surgery for unilateral CSOM and 5 patients undergoing surgery for unilateral LSB (with CTN resection) served as the comparison group. Taste function was measured using taste strips on both sides of the tongue before surgery, 2 weeks postoperatively and 3 months postoperatively. The affected side of the tongue was compared to the unaffected side. A questionnaire on taste perception was completed at each visit. Results: Preoperatively, cholesteatoma patients showed higher taste strip scores than non-cholesteatoma patients, indicating a larger difference between the healthy and affected sides of the tongue. Despite this difference in measured taste function few cholesteatoma patients reported taste alteration before surgery (3/29 [10.3%]). Postoperatively, patients with CTN resection (OMCC patients with CTN resection and LSB patients) showed a decreased measured taste function. Subjectively, only approximately 20% of these patients reported taste alteration 3 months postoperatively. Conclusions: Before surgery, cholesteatoma patients displayed an impaired measured taste function compared to patients without cholesteatoma (CSOM, LSB). Subjectively this was often unnoticed. After surgery, despite removal of the CTN and consequent reduction of measured taste function, few patients reported taste alteration and subjective taste perception was seen to be improving. In regards to middle ear surgery, perceived taste function does not seem to reflect measured gustatory function. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Neuro-oncology

Author

Fink, Karen L., Rushing, Elisabeth J., Schold, S. Clifford, Jr., and Rosenberg, Roger N., editor

Published
2003
Full Text
View/download PDF

37. Venous thromboembolic events in glioblastoma patients: An epidemiological study

Author

Eisele, Amanda; https://orcid.org/0000-0002-9791-169X, Seystahl, Katharina; https://orcid.org/0000-0002-4072-5669, Rushing, Elisabeth J; https://orcid.org/0000-0001-7616-6320, Roth, Patrick, Le Rhun, Emilie; https://orcid.org/0000-0002-9408-3278, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Gramatzki, Dorothee, Eisele, Amanda; https://orcid.org/0000-0002-9791-169X, Seystahl, Katharina; https://orcid.org/0000-0002-4072-5669, Rushing, Elisabeth J; https://orcid.org/0000-0001-7616-6320, Roth, Patrick, Le Rhun, Emilie; https://orcid.org/0000-0002-9408-3278, Weller, Michael; https://orcid.org/0000-0002-1748-174X, and Gramatzki, Dorothee

Abstract

BACKGROUND AND PURPOSE Venous thromboembolic events (VTEs) are a major complication in cancer patients, and therefore, also in brain cancer patients, anticoagulants are considered appropriate in the treatment of VTEs. METHODS Frequency, risk factors, and treatment of VTEs, as well as associated complications, were assessed in a population-based cohort of glioblastoma patients in the Canton of Zurich, Switzerland. Correlations between clinical data and survival were retrospectively analyzed using the log-rank test and Cox regression models. RESULTS Four hundred fourteen glioblastoma patients with isocitrate dehydrogenase wild-type status were identified. VTEs were documented in 65 patients (15.7%). Median time from tumor diagnosis to the occurrence of a VTE was 1.8 months, and 27 patients were diagnosed with VTEs postoperatively (within 35 days; 42.2%). History of a prior VTE was more common in patients who developed VTEs than in those who did not (p = 0.004). Bevacizumab treatment at any time during the disease course was not associated with occurrence of VTEs (p = 0.593). Most patients with VTEs (n = 61, 93.8%) were treated with therapeutic anticoagulation. Complications occurred in 14 patients (23.0%), mainly intracranial hemorrhages (n = 7, 11.5%). Overall survival did not differ between patients diagnosed with VTEs and those who had no VTE (p = 0.139). Tumor progression was the major cause of death (n = 283, 90.7%), and only three patients (1.0%) died in association with acute VTEs. CONCLUSIONS Venous thromboembolic events occurred early in the disease course, suggesting that the implementation of primary venous thromboembolism prophylaxis during first-line chemoradiotherapy could be explored in a randomized setting.

Published
2022

38. Immunohistochemical Expression Pattern of Theragnostic Targets SSTR2 and PSMA in Endolymphatic Sac Tumors: A Single Institution Case Series

Author

Brada, Muriel D, Rushing, Elisabeth J; https://orcid.org/0000-0001-7616-6320, Bächinger, David; https://orcid.org/0000-0002-6336-494X, Zoller, Loris, Burger, Irene A; https://orcid.org/0000-0001-8029-8692, Hüllner, Martin W; https://orcid.org/0000-0002-4849-3292, Moch, Holger; https://orcid.org/0000-0002-7986-2839, Huber, Alexander; https://orcid.org/0000-0002-8888-8483, Eckhard, Andreas H, Rupp, Niels J; https://orcid.org/0000-0002-7043-3456, Brada, Muriel D, Rushing, Elisabeth J; https://orcid.org/0000-0001-7616-6320, Bächinger, David; https://orcid.org/0000-0002-6336-494X, Zoller, Loris, Burger, Irene A; https://orcid.org/0000-0001-8029-8692, Hüllner, Martin W; https://orcid.org/0000-0002-4849-3292, Moch, Holger; https://orcid.org/0000-0002-7986-2839, Huber, Alexander; https://orcid.org/0000-0002-8888-8483, Eckhard, Andreas H, and Rupp, Niels J; https://orcid.org/0000-0002-7043-3456

Abstract

Background Endolymphatic sac tumors are rare neoplasia characterized by slow growth. However, their clinical impact should not be underestimated, considering their potential for local aggressive behavior and strong association with von Hippel–Lindau syndrome. Therefore, early detection with emerging theragnostic examinations such as 68Ga-DOTATATE-PET/CT might improve patient management and reduce morbidity. Methods We report the clinicopathological features of seven endolymphatic sac tumors. In this cohort, we performed immunohistochemical analysis of somatostatin receptor 2A (SSTR2A) and prostate specific membrane antigen (PSMA) protein expression patterns; two targets providing rationale for novel imaging modalities such as PSMA- or SSTR-targeted PET. Results The tumor cells of all cases were negative for prostate specific membrane antigen and somatostatin receptor 2A, however immunolabeling was consistently detected in intratumoral endothelial cells of endolymphatic sac tumors for PSMA (7/7 cases, 100%), and for SSTR2A (5/7 cases, 71%). Conclusions Our results show a high rate of PSMA and SSTR2A expression in the tumor vasculature of endolymphatic sac tumors. PSMA and SSTR2A can be targeted with appropriate radioligands for diagnostic and therapeutic purposes. This finding provides a rationale for prospective clinical studies to test this approach as a sensitive screening tool for patients with suspected endolymphatic sac tumors including an improved management of von Hippel–Lindau syndrome.

Published
2022

44. Abstract 5325: Image-based functional precision medicine for repurposing neuroactive drugs in glioblastoma

Author

Lee, Sohyon, primary, Weiss, Tobias, additional, Bühler, Marcel, additional, Wegmann, Rebekka, additional, Mena, Julien, additional, Bihl, Michel, additional, Goetze, Sandra, additional, van Drogen, Audrey, additional, Rushing, Elisabeth J., additional, Wollscheid, Bernd, additional, Weller, Michael, additional, and Snijder, Berend, additional

Published
2022
Full Text
View/download PDF

46. Cancer in children with biallelic BRCA1 variants and Fanconi anemia‐like features: Report of a malignant brain tumor in a young child

Author

Borlin, Petra R., primary, Brazzola, Pierluigi, additional, Frontzek, Karl, additional, Zanoni, Paolo, additional, Morscher, Raphael J., additional, Hench, Jurgen, additional, Frank, Stephan, additional, Kottke, Raimund, additional, Rushing, Elisabeth J., additional, Goeggel Simonetti, Barbara, additional, Steindl, Katharina, additional, and Guerreiro Stucklin, Ana S., additional

Published
2022
Full Text
View/download PDF

47. Contributing Authors

Author

Burger, Peter C., primary, Scheithauer, Bernd W., additional, Ersen, Ayca, additional, and Rushing, Elisabeth J., additional

Published
2016
Full Text
View/download PDF

48. Targeting tumour-intrinsic neural vulnerabilities of glioblastoma

Author

Lee, Sohyon, Weiss, Tobias, Bühler, Marcel, Mena, Julien, Lottenbach, Zuzanna, Wegmann, Rebekka, Bihl, Michel, Augustynek, Bartlomiej, Baumann, Sven, Goetze, Sandra, van Drogen, Audrey, Vasella, Flavio, Rushing, Elisabeth J, Wollscheid, Bernd, Hediger, Matthias A, and Snijder, Berend

Subjects
610 Medicine & health
Published
2022
Full Text
View/download PDF

49. Cancer in children with biallelic BRCA1 variants and Fanconi anemia-like features: Report of a malignant brain tumor in a young child

Author

Borlin, Petra R, Brazzola, Pierluigi, Frontzek, Karl, Zanoni, Paolo, Morscher, Raphael J, Hench, Jürgen, Frank, Stephan, Kottke, Raimund, Rushing, Elisabeth J, Goeggel Simonetti, Barbara, Steindl, Katharina, Guerreiro Stucklin, Ana S, and University of Zurich

Subjects
BRCA1 Protein, Brain Neoplasms, 10039 Institute of Medical Genetics, 10208 Institute of Neuropathology, 610 Medicine & health, Hematology, Perinatology and Child Health, Pediatrics, Fanconi Anemia, Oncology, 10036 Medical Clinic, Pediatrics, Perinatology and Child Health, Mutation, Humans, 570 Life sciences, biology, Genetic Predisposition to Disease, Child
Published
2022
Full Text
View/download PDF

50. WHO classification of tumors of the nervous system: preview of the upcoming 5th edition

Author

Rushing, Elisabeth J, University of Zurich, and Rushing, Elisabeth J

Subjects
0301 basic medicine, Nervous system, business.industry, 2720 Hematology, 610 Medicine & health, Hematology, 10040 Clinic for Neurology, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, medicine.anatomical_structure, Oncology, 10036 Medical Clinic, Medicine, 2730 Oncology, Identification (biology), business, Who classification, Neuroscience, 030217 neurology & neurosurgery
Abstract

SummaryIdentification of the underlying genetic and epigenetic alterations in an increasing number of tumors of the nervous system is contributing to a more clinically relevant classification. In the following article, the 7 cIMPACT-NOW publications, which adumbrate the upcoming 5th edition of the WHO Classification of Tumours of the Central Nervous Sytem are summarized.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results